Pfizer try to expand the use of Talzenna in prostate cancer, which was interrogated by the FDA board

A committee of FDA experts in the United States won an effort by PFIZER (New York:PFE) To expand the number of patients to treat prostate cancer (Talazoparib).

The members of the Consultative Committee of Medicines have expressed fears that the data were not strong